- Home
- GHI vs AKBA Comparison
GHI vs AKBA Comparison
Compare GHI & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- AKBA
- Stock Information
- Founded
- GHI 1998
- AKBA 2007
- Country
- GHI United States
- AKBA United States
- Employees
- GHI N/A
- AKBA N/A
- Industry
- GHI Finance: Consumer Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- AKBA Health Care
- Exchange
- GHI Nasdaq
- AKBA Nasdaq
- Market Cap
- GHI 285.3M
- AKBA 336.2M
- IPO Year
- GHI N/A
- AKBA 2014
- Fundamental
- Price
- GHI $12.21
- AKBA $1.91
- Analyst Decision
- GHI Strong Buy
- AKBA Strong Buy
- Analyst Count
- GHI 3
- AKBA 3
- Target Price
- GHI $16.50
- AKBA $6.50
- AVG Volume (30 Days)
- GHI 41.5K
- AKBA 6.0M
- Earning Date
- GHI 05-07-2025
- AKBA 05-08-2025
- Dividend Yield
- GHI 12.00%
- AKBA N/A
- EPS Growth
- GHI N/A
- AKBA N/A
- EPS
- GHI 0.76
- AKBA N/A
- Revenue
- GHI $32,275,700.00
- AKBA $160,180,000.00
- Revenue This Year
- GHI $224.89
- AKBA $23.40
- Revenue Next Year
- GHI N/A
- AKBA $58.44
- P/E Ratio
- GHI $16.22
- AKBA N/A
- Revenue Growth
- GHI N/A
- AKBA N/A
- 52 Week Low
- GHI $10.12
- AKBA $0.80
- 52 Week High
- GHI $16.25
- AKBA $2.89
- Technical
- Relative Strength Index (RSI)
- GHI 39.72
- AKBA 45.97
- Support Level
- GHI $12.44
- AKBA $1.83
- Resistance Level
- GHI $13.10
- AKBA $2.22
- Average True Range (ATR)
- GHI 0.32
- AKBA 0.21
- MACD
- GHI -0.10
- AKBA -0.03
- Stochastic Oscillator
- GHI 11.23
- AKBA 28.21
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.